Knoll Capital Management, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Knoll Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$6.04 - $9.66 $653,926 - $1.05 Million	-108,266 Reduced 15.6%	585,966 $586,000
Q4 2020 Feb 16, 2021	BUY	$7.98 - $12.29 $789,972 - $1.22 Million	98,994 Added 16.63%	694,232 $8.53 Million
Q3 2020 Nov 16, 2020	BUY	$7.96 - $12.42 $557,200 - $869,400	70,000 Added 13.33%	595,238 $4.85 Million
Q2 2020 Aug 14, 2020	BUY	$5.4 - $13.37 $270,000 - $668,500	50,000 Added 10.52%	525,238 $5.06 Million
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $613,750 - $1.84 Million	125,000 Added 35.69%	475,238 $3.23 Million
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $2.62 Million - $4.11 Million	275,000 Added 365.51%	350,238 $3.71 Million
Q1 2018 May 15, 2018	BUY	$8.1 - $16.0 $609,427 - $1.2 Million	75,238 New	75,238 $741,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $76.1M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Knoll Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Knoll Capital Management, LLC with notifications on news.